The role of complement system in adipose tissue-related inflammation

Immunologic Research

Volumn 64, Issue 3, 2016, Pages 653-664

  Vlaicu, Sonia I ^a,b   Tatomir, Alexandru ^a,c   Boodhoo, Dallas ^a   Vesa, Stefan ^b   Mircea, Petru A ^b   Rus, Horea ^a,c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Veterans Administration Multiple Sclerosis Center of Excellence   (United States)

Author keywords

Adipose tissue; C5b 9; Complement activation; Diabetes mellitus; Metabolic syndrome; RGC 32

Indexed keywords

C5 LIKE RECEPTOR 2; CD59 ANTIGEN; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3A RECEPTOR; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR D; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT RECEPTOR; MANNAN BINDING LECTIN ASSOCIATED SERINE PROTEINASE; MANNOSE BINDING LECTIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; COMPLEMENT;

ADIPOSE TISSUE; ATHEROSCLEROSIS; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DISEASE MODEL; DYSLIPIDEMIA; GENE; GENE FUNCTION; GLYCATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RGC 32 GENE; ANIMAL; ENERGY METABOLISM; IMMUNOLOGY; LIPID METABOLISM; METABOLISM;

ADIPOSE TISSUE; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENERGY METABOLISM; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; OBESITY;

EID: 84954139116     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-015-8783-5     Document Type: Review

References (124)

1. Niculescu F, Niculescu T, Rus H. C5b-9 terminal complement complex assembly on apoptotic cells in human arterial wall with atherosclerosis. Exp Mol Pathol. 2004;76:17–23.
2. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–97.
3. Vlaicu SI, Tatomir A, Rus V, Mekala AP, Mircea PA, et al. The role of complement activation in atherogenesis: the first 40 years. Immunol Res. 2015;. doi:10.1007/s12026-015-8669-6.
4. Dunkelberger JR, Song WC. Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20:34–50.
5. Cole DS, Morgan BP. Beyond lysis: how complement influences cell fate. Clin Sci (Lond). 2003;104:455–66.
6. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res. 2004;30:73–80.
7. Vlaicu SI, Tegla CA, Cudrici CD, Danoff J, Madani H, et al. Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer. Immunol Res. 2013;56:109–21.
8. Hu VW, Esser AF, Podack ER, Wisnieski BJ. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane. J Immunol. 1981;127:380–6.
9. Laine RO, Esser AF. Detection of refolding conformers of complement protein C9 during insertion into membranes. Nature. 1989;341:63–5.
10. Podack ER, Tschopp J. Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci USA. 1982;79:574–8.
11. Tschopp J, Podack ER, Muller-Eberhard HJ. The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization. J Immunol. 1985;134:495–9.
12. Whitlow MB, Ramm LE, Mayer MM. Penetration of C8 and C9 in the C5b-9 complex across the erythrocyte membrane into the cytoplasmic space. J Biol Chem. 1985;260:998–1005.
13. Tegla CA, Cudrici C, Patel S, Trippe R 3rd, Rus V, et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011;51:45–60.
14. Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis. 2014;233:104–12.
15. Richardson VR, Smith KA, Carter AM. Adipose tissue inflammation: feeding the development of type 2 diabetes mellitus. Immunobiology. 2013;218:1497–504.
16. Cianflone K, Maslowska M. Differentiation-induced production of ASP in human adipocytes. Eur J Clin Invest. 1995;25:817–25.
17. Phieler J, Garcia-Martin R, Lambris JD, Chavakis T. The role of the complement system in metabolic organs and metabolic diseases. Semin Immunol. 2013;25:47–53.
18. Sissons JG, West RJ, Fallows J, Williams DG, Boucher BJ, et al. The complement abnormalities of lipodystrophy. N Engl J Med. 1976;294:461–5.
19. McLean RH, Hoefnagel D. Partial lipodystrophy and familial C3 deficiency. Hum Hered. 1980;30:149–54.
20. White RT, Damm D, Hancock N, Rosen BS, Lowell BB, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem. 1992;267:9210–3.
21. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem. 1992;267:12736–41.
22. Peake PW, O’Grady S, Pussell BA, Charlesworth JA. Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes. Eur J Clin Invest. 1997;27:922–7.
23. Mathieson PW, Wurzner R, Oliveria DB, Lachmann PJ, Peters DK. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med. 1993;177:1827–31.
24. Barbu A, Hamad OA, Lind L, Ekdahl KN, Nilsson B. The role of complement factor C3 in lipid metabolism. Mol Immunol. 2015;67:101–7.
25. Gauvreau D, Roy C, Tom FQ, Lu H, Miegueu P, et al. A new effector of lipid metabolism: complement factor properdin. Mol Immunol. 2012;51:73–81.
26. Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: an emerging risk factor in cardiometabolic disease. Diabetologia. 2012;55:881–4.
27. MacLaren RE, Cui W, Lu H, Simard S, Cianflone K. Association of adipocyte genes with ASP expression: a microarray analysis of subcutaneous and omental adipose tissue in morbidly obese subjects. BMC Med Genomics. 2010;3:3.
28. Moreno-Navarrete JM, Martinez-Barricarte R, Catalan V, Sabater M, Gomez-Ambrosi J, et al. Complement factor H is expressed in adipose tissue in association with insulin resistance. Diabetes. 2010;59:200–9.
29. Gabrielsson BG, Johansson JM, Lonn M, Jernas M, Olbers T, et al. High expression of complement components in omental adipose tissue in obese men. Obes Res. 2003;11:699–708.
30. Gupta A, Rezvani R, Lapointe M, Poursharifi P, Marceau P, et al. Downregulation of complement C3 and C3aR expression in subcutaneous adipose tissue in obese women. PLoS ONE. 2014;9:e95478.
31. Hillian AD, McMullen MR, Sebastian BM, Roychowdhury S, Kashyap SR, et al. Mice lacking C1q are protected from high fat diet-induced hepatic insulin resistance and impaired glucose homeostasis. J Biol Chem. 2013;288:22565–75.
32. Diawara MR, Hue C, Wilder SP, Venteclef N, Aron-Wisnewsky J, et al. Adaptive expression of microRNA-125a in adipose tissue in response to obesity in mice and men. PLoS ONE. 2014;9:e91375.
33. van Greevenbroek MM, Ghosh S, van der Kallen CJ, Brouwers MC, Schalkwijk CG, et al. Up-regulation of the complement system in subcutaneous adipocytes from nonobese, hypertriglyceridemic subjects is associated with adipocyte insulin resistance. J Clin Endocrinol Metab. 2012;97:4742–52.
34. Cero C, Vostrikov VV, Verardi R, Severini C, Gopinath T, et al. The TLQP-21 peptide activates the G-protein-coupled receptor C3aR1 via a folding-upon-binding mechanism. Structure. 2014;22:1744–53.
35. Lim J, Iyer A, Suen JY, Seow V, Reid RC, et al. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. Faseb J. 2013;27:822–31.
36. Mamane Y, Chung Chan C, Lavallee G, Morin N, Xu LJ, et al. The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes. 2009;58:2006–17.
37. Schaffler A, Scholmerich J. Innate immunity and adipose tissue biology. Trends Immunol. 2010;31:228–35.
38. Blogowski W, Budkowska M, Salata D, Serwin K, Dolegowska B, et al. Clinical analysis of selected complement-derived molecules in human adipose tissue. J Transl Med. 2013;11:11.
39. Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche-von Ameln A, Garcia-Martin R, et al. The complement anaphylatoxin C5a receptor contributes to obese adipose tissue inflammation and insulin resistance. J Immunol. 2013;191:4367–74.
40. Zhang J, Wright W, Bernlohr DA, Cushman SW, Chen X. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2007;292:E1433–40.
41. Fraser DA, Laust AK, Nelson EL, Tenner AJ. C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. J Immunol. 2009;183:6175–85.
42. Alkhouri N, Gornicka A, Berk MP, Thapaliya S, Dixon LJ, et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem. 2010;285:3428–38.
43. Cianflone K, Zakarian R, Couillard C, Delplanque B, Despres JP, et al. Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance. J Lipid Res. 2004;45:124–31.
44. MacLaren R, Cui W, Cianflone K. Adipokines and the immune system: an adipocentric view. Adv Exp Med Biol. 2008;632:1–21.
45. Maslowska M, Sniderman AD, Germinario R, Cianflone K. ASP stimulates glucose transport in cultured human adipocytes. Int J Obes Relat Metab Disord. 1997;21:261–6.
46. Murray I, Sniderman AD, Cianflone K. Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. Am J Physiol. 1999;277:E474–80.
47. Murray I, Sniderman AD, Cianflone K. Mice lacking acylation stimulating protein (ASP) have delayed postprandial triglyceride clearance. J Lipid Res. 1999;40:1671–6.
48. Badea TC, Niculescu FI, Soane L, Shin ML, Rus H. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J Biol Chem. 1998;273:26977–81.
49. Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H, et al. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J Biol Chem. 2002;277:502–8.
50. Tegla CA, Cudrici CD, Nguyen V, Danoff J, Kruszewski AM, et al. RGC-32 is a novel regulator of the T-lymphocyte cell cycle. Exp Mol Pathol. 2015;98:328–37.
51. Vlaicu SI, Cudrici C, Ito T, Fosbrink M, Tegla CA, et al. Role of response gene to complement 32 in diseases. Arch Immunol Ther Exp (Warsz). 2008;56:115–22.
52. Wang JN, Shi N, Xie WB, Guo X, Chen SY. Response gene to complement 32 promotes vascular lesion formation through stimulation of smooth muscle cell proliferation and migration. Arterioscler Thromb Vasc Biol. 2011;31:e19–26.
53. Fosbrink M, Cudrici C, Tegla CA, Soloviova K, Ito T, et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp Mol Pathol. 2009;86:87–94.
54. Cui XB, Guo X, Chen SY. Response gene to complement 32 deficiency causes impaired placental angiogenesis in mice. Cardiovasc Res. 2013;99:632–9.
55. Guo S, Philbrick MJ, An X, Xu M, Wu J. Response gene to complement 32 (RGC-32) in endothelial cells is induced by glucose and helpful to maintain glucose homeostasis. Int J Clin Exp Med. 2014;7:2541–9.
56. Cui XB, Luan JN, Ye J, Chen SY. RGC32 deficiency protects against high-fat diet-induced obesity and insulin resistance in mice. J Endocrinol. 2015;224:127–37.
57. Ghosh P, Sahoo R, Vaidya A, Chorev M, Halperin JA. Role of complement and complement regulatory proteins in the complications of diabetes. Endocr Rev. 2015;36:272–88.
58. Guan LZ, Tong Q, Xu J. Elevated serum levels of mannose-binding lectin and diabetic nephropathy in type 2 diabetes. PLoS ONE. 2015;10:e0119699.
59. Geng P, Ding Y, Qiu L, Lu Y. Serum mannose-binding lectin is a strong biomarker of diabetic retinopathy in chinese patients with diabetes. Diabetes Care. 2015;38:868–75.
60. Hovind P, Hansen TK, Tarnow L, Thiel S, Steffensen R, et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: an inception cohort study. Diabetes. 2005;54:1523–7.
61. Jenny L, Ajjan R, King R, Thiel S, Schroeder V. Plasma levels of mannan-binding lectin-associated serine proteases MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control. Clin Exp Immunol. 2015;180:227–32.
62. Vlaicu R, Niculescu F, Rus HG, Cristea A. Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis. 1985;57:163–77.
63. Niculescu F, Hugo F, Rus HG, Vlaicu R, Bhakdi S. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries. Clin Exp Immunol. 1987;69:477–83.
64. Niculescu F, Rus HG, Vlaicu R. Activation of the human terminal complement pathway in atherosclerosis. Clin Immunol Immunopathol. 1987;45:147–55.
65. Rus HG, Niculescu F, Constantinescu E, Cristea A, Vlaicu R. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis. 1986;61:35–42.
66. Rus HG, Niculescu F, Porutiu D, Ghiurca V, Vlaicu R. Cells carrying C5b-9 complement complexes in human atherosclerotic wall. Immunol Lett. 1989;20:305–10.
67. Niculescu F, Badea T, Rus H. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells: role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis. 1999;142:47–56.
68. Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem. 2006;281:19009–18.
69. Vasil KE, Magro CM. Cutaneous vascular deposition of C5b-9 and its role as a diagnostic adjunct in the setting of diabetes mellitus and porphyria cutanea tarda. J Am Acad Dermatol. 2007;56:96–104.
70. Falk RJ, Sisson SP, Dalmasso AP, Kim Y, Michael AF, et al. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis. 1987;9:121–8.
71. Gerl VB, Bohl J, Pitz S, Stoffelns B, Pfeiffer N, et al. Extensive deposits of complement C3d and C5b-9 in the choriocapillaris of eyes of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2002;43:1104–8.
72. Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N, et al. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol. 2000;99:55–62.
73. Mellbin LG, Bjerre M, Thiel S, Hansen TK. Complement activation and prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Diabetes Care. 2012;35:911–7.
74. Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes. 2004;53:2653–61.
75. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA. 2000;97:5450–5.
76. Ghosh P, Vaidya A, Sahoo R, Goldfine A, Herring N, et al. Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans. J Clin Endocrinol Metab. 2014;99:E999–1006.
77. Krus U, King BC, Nagaraj V, Gandasi NR, Sjolander J, et al. The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events. Cell Metab. 2014;19:883–90.
78. Hoffman WH, Cudrici CD, Zafranskaia E, Rus H. Complement activation in diabetic ketoacidosis brains. Exp Mol Pathol. 2006;80:283–8.
79. Jerath RS, Burek CL, Hoffman WH, Passmore GG. Complement activation in diabetic ketoacidosis and its treatment. Clin Immunol. 2005;116:11–7.
80. Niculescu F, Soane L, Badea T, Shin M, Rus H. Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology. 1999;42:187–93.
81. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179:985–92.
82. Halperin JA, Taratuska A, Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest. 1993;91:1974–8.
83. Saleh J, Al-Wardy N, Farhan H, Al-Khanbashi M, Cianflone K. Acylation stimulating protein: a female lipogenic factor? Obes Rev. 2011;12:440–8.
84. Yasruel Z, Cianflone K, Sniderman AD, Rosenbloom M, Walsh M, et al. Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids. 1991;26:495–9.
85. Cianflone K, Maslowska M, Sniderman AD. Acylation stimulating protein (ASP), an adipocyte autocrine: new directions. Semin Cell Dev Biol. 1999;10:31–41.
86. Murray I, Havel PJ, Sniderman AD, Cianflone K. Reduced body weight, adipose tissue, and leptin levels despite increased energy intake in female mice lacking acylation-stimulating protein. Endocrinology. 2000;141:1041–9.
87. Murray I, Sniderman AD, Havel PJ, Cianflone K. Acylation stimulating protein (ASP) deficiency alters postprandial and adipose tissue metabolism in male mice. J Biol Chem. 1999;274:36219–25.
88. Xia Z, Stanhope KL, Digitale E, Simion OM, Chen L, et al. Acylation-stimulating protein (ASP)/complement C3adesArg deficiency results in increased energy expenditure in mice. J Biol Chem. 2004;279:4051–7.
89. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. 2005;37:710–7.
90. Munkonda MN, Lapointe M, Miegueu P, Roy C, Gauvreau D, et al. Recombinant acylation stimulating protein administration to C3-/- mice increases insulin resistance via adipocyte inflammatory mechanisms. PLoS ONE. 2012;7:e46883.
91. Fisette A, Lapointe M, Cianflone K. Obesity-inducing diet promotes acylation stimulating protein resistance. Biochem Biophys Res Commun. 2013;437:403–7.
92. Paglialunga S, Schrauwen P, Roy C, Moonen-Kornips E, Lu H, et al. Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J Endocrinol. 2007;194:293–304.
93. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol (Lausanne). 2013;4:37.
94. Lo JC, Ljubicic S, Leibiger B, Kern M, Leibiger IB, et al. Adipsin is an adipokine that improves beta cell function in diabetes. Cell. 2014;158:41–53.
95. Cianflone K, Lu H, Smith J, Yu W, Wang H. Adiponectin, acylation stimulating protein and complement C3 are altered in obesity in very young children. Clin Endocrinol (Oxf). 2005;62:567–72.
96. Engström G, Hedblad B, Eriksson K-F, Janzon L, Lindgärde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. 2005;54:570–5.
97. Engstrom G, Hedblad B, Janzon L, Lindgarde F. Weight gain in relation to plasma levels of complement factor 3: results from a population-based cohort study. Diabetologia. 2005;48:2525–31.
98. Nilsson B, Hamad OA, Ahlstrom H, Kullberg J, Johansson L, et al. C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur J Clin Invest. 2014;44:587–96.
99. Onat A, Uyarel H, Hergenc G, Karabulut A, Albayrak S, et al. Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis. 2007;191:182–90.
100. Qin X, Lu Y, Yang X, Peng Q, Wang J, et al. Determination of reference intervals for serum complement C3 and C4 levels in Chinese Han ethnic males. Clin Lab. 2014;60:775–81.
101. Warnberg J, Nova E, Moreno LA, Romeo J, Mesana MI, et al. Inflammatory proteins are related to total and abdominal adiposity in a healthy adolescent population: the AVENA Study. Am J Clin Nutr. 2006;84:505–12.
102. Hernandez-Mijares A, Jarabo-Bueno MM, Lopez-Ruiz A, Sola-Izquierdo E, Morillas-Arino C, et al. Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes (Lond). 2007;31:927–32.
103. Oberbach A, Bluher M, Wirth H, Till H, Kovacs P, et al. Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J Proteome Res. 2011;10:4769–88.
104. Sleddering MA, Markvoort AJ, Dharuri HK, Jeyakar S, Snel M, et al. Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers. PLoS ONE. 2014;9:e112835.
105. Nestvold TK, Nielsen EW, Ludviksen JK, Fure H, Landsem A, et al. Lifestyle changes followed by bariatric surgery lower inflammatory markers and the cardiovascular risk factors C3 and C4. Metab Syndr Relat Disord. 2015;13:29–35.
106. Wlazlo N, van Greevenbroek MM, Ferreira I, Jansen EJ, Feskens EJ, et al. Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism. 2012;61:1787–96.
107. Phillips CM, Kesse-Guyot E, Ahluwalia N, McManus R, Hercberg S, et al. Dietary fat, abdominal obesity and smoking modulate the relationship between plasma complement component 3 concentrations and metabolic syndrome risk. Atherosclerosis. 2012;220:513–9.
108. Wlazlo N, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, et al. Complement factor 3 is associated with insulin resistance and with incident type 2 diabetes over a 7-year follow-up period: the CODAM Study. Diabetes Care. 2014;37:1900–9.
109. De Pergola G, Tartagni M, Bartolomeo N, Bruno I, Masiello M, et al. Possible direct influence of complement 3 in decreasing insulin sensitivity in a cohort of overweight and obese subjects. Endocr Metab Immune Disord Drug Targets. 2013;13:301–5.
110. Muscari A, Antonelli S, Bianchi G, Cavrini G, Dapporto S, et al. Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate: comparison study in an elderly population. Diabetes Care. 2007;30:2362–8.
111. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, et al. Association of serum C3 levels with the risk of myocardial infarction. Am J Med. 1995;98:357–64.
112. Vidigal Fde C, Ribeiro AQ, Babio N, Salas-Salvado J, Bressan J. Prevalence of metabolic syndrome and pre-metabolic syndrome in health professionals: LATINMETS Brazil study. Diabetol Metab Syndr. 2015;7:6.
113. Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412:1171–9.
114. Van Harmelen V, Reynisdottir S, Cianflone K, Degerman E, Hoffstedt J, et al. Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J Biol Chem. 1999;274:18243–51.
115. Ahren B, Havel PJ, Pacini G, Cianflone K. Acylation stimulating protein stimulates insulin secretion. Int J Obes Relat Metab Disord. 2003;27:1037–43.
116. Saleh J, Wahab RA, Farhan H, Al-Amri I, Cianflone K. Plasma levels of acylation-stimulating protein are strongly predicted by waist/hip ratio and correlate with decreased LDL size in men. ISRN Obes. 2013;2013:342802.
117. Yang Y, Lu HL, Zhang J, Yu HY, Wang HW, et al. Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes (Lond). 2006;30:439–46.
118. Cianflone K, Zhang XJ, Genest J Jr, Sniderman A. Plasma acylation-stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:1239–44.
119. Weyer C, Pratley RE. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. Obes Res. 1999;7:444–52.
120. Wamba PC, Mi J, Zhao XY, Zhang MX, Wen Y, et al. Acylation stimulating protein but not complement C3 associates with metabolic syndrome components in Chinese children and adolescents. Eur J Endocrinol. 2008;159:781–90.
121. Fujita T, Hemmi S, Kajiwara M, Yabuki M, Fuke Y, et al. Complement-mediated chronic inflammation is associated with diabetic microvascular complication. Diabetes Metab Res Rev. 2013;29:220–6.
122. Somani R, Richardson VR, Standeven KF, Grant PJ, Carter AM. Elevated properdin and enhanced complement activation in first-degree relatives of South Asian subjects with type 2 diabetes. Diabetes Care. 2012;35:894–9.
123. Uza G, Cristea A, Cucuianu MP. Increased level of the complement C3 protein in endogenous hypertriglyceridemia. J Clin Lab Immunol. 1982;8:101–5.
124. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117:746–56.